Musika wepasi rose antiviral mishonga yemusika unotarisirwa kusvika pamadhora mazana mashanu nemakumi mashanu emadhora muna 50.02 uye kunyoresa mari CAGR ye2030% panguva yekufanotaura, sekureva kwazvino mushumo weReports uye Dhata. Kuvandudzwa kwezvinyowani, zvakagadziridzwa, uye kugadzirwa kwezvinodhaka chinhu chakakosha chinotarisirwa kufambisa kukura kwemari yemusika panguva yekufanotaura. Kuwedzera kweCCIDID-3.4 kesi, pamwe nekuenderera mberi kwekuwanikwa kwepombi yakasimba yechigadzirwa chemishonga inorwisa mabhakitiriya, inotarisirwa kutsigira mari yekukura kwemusika panguva yekufanotaura. Nzira dzazvino dzekugadzira mishonga yekudzivirira hutachiona, senge mishonga yakadzokororwa, yave kutariswa, sezvavanoongorora nzira nyowani dzekudzorerazve mishonga yakabvumidzwa nekutengeserana kana kurambwa yagara iripo yekurapa hutachiona hwekufema. Kubudirira kwekurapa nzira dzehutachiona hwehutachiona, seCCIDID-19, Human Immunodeficiency Virus (HIV), uye Human Coronavirus (HCoV), parizvino inosanganisira maviri kana anopfuura musanganiswa wemishonga, sezvo vachigona kumisa kukura kwekuramba zvinodhaka. Aya maitiro anogona kubatsira kugadzirisa kubuda mumamiriro ezvinhu akaoma, panguva uye inodhura.
Kukura kwakasiyana-siyana kwehutachiona kunogona kudzora musika kukura kwemari panguva yekufanotaura. Hutachiona hunochinja nekukurumidza nekufamba kwenguva, zvichiita kuti mishonga yechivanhu inorwisa utachiona husashande, kana kusashanda. Naizvozvo, mishonga inorwisa mavhairasi inoshanda kurwisa akasiyana siyana ekufema mavhairasi inofanirwa kuvandudzwa nguva dzose kuitira kudzivirira hutachiona hwekufema zvirwere mune ramangwana. Makambani makuru emishonga ari kuuya nevatsva vemishonga yekurwisa hutachiona kuti vazadzise kudiwa kuri kuramba kuchikwira, izvo zviri kutsigira kukura kwemari yemusika. Pfizer PFE neMerck MRK, iyo inotengesa Paxlovid nemolnupiravir, zvichiteerana, iri kutonga musika weCCIDID-19 antiviral kurapwa muUS The Food and Drug Administration (FDA) yakabvumidza Paxlovid uye molnupiravir senge mitsva yemuromo antiviral mushonga sarudzo kune vasina-chipatara COVID- 19 uye akavabvumidza kushandiswa kwechimbichimbi muna Zvita 2021.
ZVOKUBVA MUNYAYA INO:
- Increase in COVID-19 cases, as well as continuous availability of a robust product pipeline of antiviral drugs, are expected to support market growth revenue during the forecast period.
- The Food and Drug Administration (FDA) approved Paxlovid and molnupiravir as new oral antiviral drug options for non-hospitalized COVID-19 infections and authorized them for emergency use in December 2021.
- Pfizer PFE and Merck MRK, which market Paxlovid and molnupiravir, respectively, are dominating the COVID-19 antiviral treatment market in the U.
